Satsuma Pharmaceuticals Current Ratio vs. Return On Asset

STSADelisted Stock  USD 1.10  0.01  0.90%   
Based on Satsuma Pharmaceuticals' profitability indicators, Satsuma Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Satsuma Pharmaceuticals' ability to earn profits and add value for shareholders.
For Satsuma Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Satsuma Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Satsuma Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Satsuma Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Satsuma Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Please note, there is a significant difference between Satsuma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Satsuma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Satsuma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Satsuma Pharmaceuticals Return On Asset vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Satsuma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Satsuma Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Satsuma Pharmaceuticals is rated below average in current ratio category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Satsuma Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Satsuma Return On Asset vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Satsuma Pharmaceuticals

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
9.18 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Satsuma Pharmaceuticals

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.5
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Satsuma Return On Asset Comparison

Satsuma Pharmaceuticals is currently under evaluation in return on asset category among its peers.

Satsuma Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Satsuma Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Satsuma Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Satsuma Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Satsuma Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Satsuma Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people.

Satsuma Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Satsuma Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Satsuma Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Satsuma Pharmaceuticals' important profitability drivers and their relationship over time.

Use Satsuma Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Satsuma Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Satsuma Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Satsuma Pharmaceuticals Pair Trading

Satsuma Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Satsuma Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Satsuma Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Satsuma Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Satsuma Pharmaceuticals to buy it.
The correlation of Satsuma Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Satsuma Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Satsuma Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Satsuma Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Satsuma Pharmaceuticals position

In addition to having Satsuma Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Drugs Thematic Idea Now

Drugs
Drugs Theme
Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. The Drugs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Drugs Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Consideration for investing in Satsuma Stock

If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance